iScience (Nov 2023)

FUS-dependent microRNA deregulations identify TRIB2 as a druggable target for ALS motor neurons

  • Wan Yun Ho,
  • Li-Ling Chak,
  • Jin-Hui Hor,
  • Fujia Liu,
  • Sandra Diaz-Garcia,
  • Jer-Cherng Chang,
  • Emma Sanford,
  • Maria J. Rodriguez,
  • Durgadevi Alagappan,
  • Su Min Lim,
  • Yik-Lam Cho,
  • Yuji Shimizu,
  • Alfred Xuyang Sun,
  • Sheue-Houy Tyan,
  • Edward Koo,
  • Seung Hyun Kim,
  • John Ravits,
  • Shi-Yan Ng,
  • Katsutomo Okamura,
  • Shuo-Chien Ling

Journal volume & issue
Vol. 26, no. 11
p. 108152

Abstract

Read online

Summary: MicroRNAs (miRNAs) modulate mRNA expression, and their deregulation contributes to various diseases including amyotrophic lateral sclerosis (ALS). As fused in sarcoma (FUS) is a causal gene for ALS and regulates biogenesis of miRNAs, we systematically analyzed the miRNA repertoires in spinal cords and hippocampi from ALS-FUS mice to understand how FUS-dependent miRNA deregulation contributes to ALS. miRNA profiling identified differentially expressed miRNAs between different central nervous system (CNS) regions as well as disease states. Among the up-regulated miRNAs, miR-1197 targets the pro-survival pseudokinase Trib2. A reduced TRIB2 expression was observed in iPSC-derived motor neurons from ALS patients. Pharmacological stabilization of TRIB2 protein with a clinically approved cancer drug rescues the survival of iPSC-derived human motor neurons, including those from a sporadic ALS patient. Collectively, our data indicate that miRNA profiling can be used to probe the molecular mechanisms underlying selective vulnerability, and TRIB2 is a potential therapeutic target for ALS.

Keywords